Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
73.00
-0.53 (-0.72%)
Jan 20, 2026, 9:43 AM EST - Market open
Spruce Biosciences Employees
Spruce Biosciences had 21 employees as of December 31, 2024. The number of employees decreased by 8 or -27.59% compared to the previous year.
Employees
21
Change (1Y)
-8
Growth (1Y)
-27.59%
Revenue / Employee
$33,190
Profits / Employee
-$2,279,952
Market Cap
78.14M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 21 | -8 | -27.59% |
| Dec 31, 2023 | 29 | 2 | 7.41% |
| Dec 31, 2022 | 27 | 12 | 80.00% |
| Dec 31, 2021 | 15 | -2 | -11.76% |
| Dec 31, 2020 | 17 | 2 | 13.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SPRB News
- 1 day ago - Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration - PRNewsWire
- 12 days ago - Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital - Business Wire
- 5 weeks ago - Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors - Business Wire
- 2 months ago - Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - Business Wire
- 3 months ago - Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade) - Seeking Alpha
- 3 months ago - This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug. - Barrons
- 3 months ago - Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 4 months ago - Spruce Biosciences Resumes Trading on the Nasdaq Capital Market - Business Wire